![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Flurazepam is a long acting drug with sedative, hypnotic, anxiolytic, relaxant, and anti-epileptic properties. The drug is a benzodiazepine and is commonly used by adults, including pregnant women, intentionally or sometimes unintentionally during their pregnancy. It is increasingly used these days, and therefore, it seems a special problem to the clinician treating anxiety disorders in women. It should be noticed that flurazepam exposure during pregnancy may have teratogenic effects on the fetus. Until now, many studies have been conducted on drug side-effects in poisonings, behavioral disorder, and anxiety reactions, but there is no accurate report about the teratogenic effect of flurazepam. In this study, teratogenicity flurazepam intake during pregnancy and its effects on fetus development was investigated. About 30 virgin rats of known age and weight were used. After being pregnant, they were divided into three groups: Negative and positive control group, case groups exposed for 1 to 6 mg/kg/day. The fetuses were first studied macroscopically regarding anomalies, and then histological and histochemically to inspect the defects of tissue organogenesis. Our results show that there was significant difference in the weight and length of the cases compared to the control group. The statistical results indicate that flurazepam intake during the second half of pregnancy can lead to irreversible anomalies. It seems that benzodiazepine therapy among pregnant woman would be better to avoid during the first trimester and multidrug regimens.